Early cancer detection requires more than single-biomarker tests can deliver. This application note explains how multiplex immunoassays reveal the complex cytokine and protein interactions that drive tumor biology—using minimal sample volumes and delivering higher sensitivity, throughput, and biological insight.
R&D Systems™ Assays for Luminex® Instruments combine validated antibodies, optimized diluents, and broad analyte coverage to ensure accurate, reproducible results even in challenging serum or plasma matrices. The note also introduces the 28-plex Human Tumor Biomarker Performance Panel, designed for preservative plasma tubes to support stable, high-quality multiplex profiling.
A featured case study, Oncuria®, demonstrates how high-performance multiplex assays can progress from research tools to clinically impactful diagnostics.
